Prothena Corporation plc – NASDAQ:PRTA
Prothena Corporation stock price today
$8.52
-6.62
-43.73%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Prothena Corporation stock price monthly change
-32.62%
month
Prothena Corporation stock price quarterly change
-32.62%
quarter
Prothena Corporation stock price yearly change
-60.03%
year
Prothena Corporation key metrics
Market Cap | 811.16M |
Enterprise value | 1.64B |
P/E | -19.88 |
EV/Sales | 30.60 |
EV/EBITDA | -15.72 |
Price/Sales | 43.66 |
Price/Book | 3.78 |
PEG ratio | 0.07 |
EPS | -3.21 |
Revenue | 89.25M |
EBITDA | -210.35M |
Income | -172.40M |
Revenue Q/Q | -97.69% |
Revenue Y/Y | 62.50% |
Profit margin | -216.95% |
Oper. margin | -244.05% |
Gross margin | 2.43% |
EBIT margin | -244.05% |
EBITDA margin | -235.69% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProthena Corporation stock price history
Prothena Corporation stock forecast
Prothena Corporation financial statements
| Jun 2023 | 4.01M | -54.59M | -1358.42% |
|---|---|---|---|
| Sep 2023 | 84.86M | 21.90M | 25.81% |
| Dec 2023 | 316K | -67.47M | -21353.16% |
| Mar 2024 | 50K | -72.23M | -144478% |
| Mar 2024 | 50K | -72.23M | -144478% |
|---|---|---|---|
| Sep 2025 | 468.87K | -78.62M | -16768.75% |
| Oct 2025 | 70.12K | -84.06M | -119880.22% |
| Dec 2025 | 38.13M | -87.55M | -229.62% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-03 | -1.77859 | -0.97 |
|---|---|---|
| 2022-12-31 | 0.649 | 0.134 |
| 2023-02-23 | -0.03092 | 0.12 |
| Jun 2023 | 720649000 | 138.97M | 19.28% |
|---|---|---|---|
| Sep 2023 | 746920000 | 129.69M | 17.36% |
| Dec 2023 | 696382000 | 135.01M | 19.39% |
| Mar 2024 | 623194000 | 120.79M | 19.38% |
| Jun 2023 | -44.92M | -771K | 18.62M |
|---|---|---|---|
| Sep 2023 | 9.51M | -442K | 2.71M |
| Dec 2023 | -51.03M | -1.51M | 483K |
| Mar 2024 | -73.05M | -103K | 836K |
Prothena Corporation alternative data
| Aug 2023 | 127 |
|---|---|
| Sep 2023 | 127 |
| Oct 2023 | 127 |
| Nov 2023 | 127 |
| Dec 2023 | 127 |
| Jan 2024 | 127 |
| Feb 2024 | 127 |
| Mar 2024 | 173 |
| Apr 2024 | 173 |
| May 2024 | 173 |
| Jun 2024 | 173 |
| Jul 2024 | 173 |
Prothena Corporation other data
90.81%
+7.19%
of PRTA is owned by hedge funds
150
-28
44.01M
+1.19M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 0 | 10000 |
| Mar 2023 | 0 | 67000 |
| Apr 2023 | 0 | 10000 |
| May 2023 | 0 | 165000 |
| Jun 2023 | 0 | 66333 |
| Jul 2023 | 0 | 30000 |
| Aug 2023 | 0 | 25000 |
| Sep 2023 | 0 | 21000 |
| Oct 2023 | 0 | 14000 |
| Nov 2023 | 0 | 5000 |
| Dec 2023 | 0 | 5000 |
| Jan 2024 | 0 | 5000 |
| Quarter | Transcript |
|---|---|
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q4 2022 24 Feb 2023 | Q4 2022 Earnings Call Transcript |
| Q4 2021 17 Feb 2022 | Q4 2021 Earnings Call Transcript |
| Q4 2020 11 Feb 2021 | Q4 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Gene G. Kinney Ph.D. (1969) Pres, Chief Executive Officer & Director | $901,120 |
Mr. Tran B. Nguyen M.B.A. (1974) Chief Financial Officer & Chief Strategy Officer | $679,370 |
| Ms. Carol D. Karp (1953) Chief Regulatory Officer | $624,390 |
| Mr. Michael J. Malecek (1966) Chief Legal Officer & Company Sec. | $588,250 |
| Mr. Brandon S. Smith (1975) Chief Operating Officer | $580,920 |
June 2024 New Analysts Cover Uber, TG Therapeutics, CarMax, And More
Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise
Prothena: Dunn Appointment And Bristol Opt-In Boost Validation
Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future
Trading Ideas On The Upcoming CTAD 2022 Conference
Acumen: ACU193 Is A Promising Phase 1 Alzheimer's Candidate, But Not More Than That
Prothena: A Biotech Company With A Promising Pipeline
-
What's the price of Prothena Corporation stock today?
One share of Prothena Corporation stock can currently be purchased for approximately $8.52.
-
When is Prothena Corporation's next earnings date?
Unfortunately, Prothena Corporation's (PRTA) next earnings date is currently unknown.
-
Does Prothena Corporation pay dividends?
No, Prothena Corporation does not pay dividends.
-
How much money does Prothena Corporation make?
Prothena Corporation has a market capitalization of 811.16M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 69.5% to 91.37M US dollars. Prothena Corporation made a loss 147.03M US dollars in net income (profit) last year or $0.12 on an earnings per share basis.
-
What is Prothena Corporation's stock symbol?
Prothena Corporation plc is traded on the NASDAQ under the ticker symbol "PRTA".
-
What is Prothena Corporation's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Prothena Corporation?
Shares of Prothena Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Prothena Corporation's key executives?
Prothena Corporation's management team includes the following people:
- Dr. Gene G. Kinney Ph.D. Pres, Chief Executive Officer & Director(age: 56, pay: $901,120)
- Mr. Tran B. Nguyen M.B.A. Chief Financial Officer & Chief Strategy Officer(age: 51, pay: $679,370)
- Ms. Carol D. Karp Chief Regulatory Officer(age: 72, pay: $624,390)
- Mr. Michael J. Malecek Chief Legal Officer & Company Sec.(age: 59, pay: $588,250)
- Mr. Brandon S. Smith Chief Operating Officer(age: 50, pay: $580,920)
-
How many employees does Prothena Corporation have?
As Jul 2024, Prothena Corporation employs 173 workers.
-
When Prothena Corporation went public?
Prothena Corporation plc is publicly traded company for more then 12 years since IPO on 18 Dec 2012.
-
What is Prothena Corporation's official website?
The official website for Prothena Corporation is prothena.com.
-
How can i contact Prothena Corporation?
Prothena Corporation can be reached via phone at +353 1 236 2500.
Prothena Corporation company profile:
Prothena Corporation plc
prothena.comExchange:
NASDAQ
Full time employees:
173
Industry:
Biotechnology
Sector:
Healthcare
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
77 Sir John Rogerson’s Quay
Dublin, 2
Dublin, 2
CIK: 0001559053
ISIN: IE00B91XRN20
CUSIP: G72800108
